Influencing the decline of lung function in COPD: use of pharmacotherapy.

International Journal of Chronic Obstructive Pulmonary Disease
Ekaterina S GladyshevaRobert L Owens

Abstract

Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. One of the hallmarks of COPD is an accelerated decline in lung function, as measured by spirometry. Inflammation, oxidative stress and other pathways are hypothesized to be important in this deterioration. Because progressive airflow obstruction is associated with considerable morbidity and mortality, a major goal of COPD treatment has been to slow or prevent the accelerated decline in lung function. Until recently, the only known effective intervention was smoking cessation. However, newly reported large clinical trials have shown that commonly used medications may help slow the rate of lung function decline. The effect of these medications is modest (and thus required such large, expensive trials) and to be of clinical benefit, therapy would likely need to start early in the course of disease and be prolonged. Such a treatment strategy aimed at preservation of lung function would need to be balanced against the side effects and costs of prolonged therapy. A variety of newer classes of medications may help target other pathophysiologically important pathways, and could be used in the future to prevent lung function decline in COPD.

References

Jun 25, 1977·British Medical Journal·C Fletcher, R Peto
Feb 1, 1975·Chest·W M Thurlbeck, G E Angus
Oct 1, 1988·The American Review of Respiratory Disease·I B TagerS T Weiss
Aug 1, 1995·American Journal of Respiratory and Critical Care Medicine·K TolepS G Kelsen
Feb 1, 1994·American Journal of Respiratory and Critical Care Medicine·P L EnrightR E Hyatt
Sep 26, 1996·The New England Journal of Medicine·D R GoldD W Dockery
May 1, 1997·American Journal of Respiratory and Critical Care Medicine·M I PolkeyJ Moxham
Oct 22, 1998·The New England Journal of Medicine·P LangeG Jensen
Feb 15, 2000·American Journal of Respiratory and Critical Care Medicine·P D ScanlonUNKNOWN Lung Health Study Research Group
Jun 3, 2000·The European Respiratory Journal·J P JanssensL P Nicod
Jan 3, 2001·The New England Journal of Medicine·UNKNOWN Lung Health Study Research GroupMelissa Skeans
Aug 14, 2001·American Journal of Respiratory and Critical Care Medicine·R E KannerUNKNOWN Lung Health Study Research Group
Aug 16, 2002·The New England Journal of Medicine·Sanjay SethiTimothy F Murphy
Aug 21, 2002·American Journal of Respiratory and Critical Care Medicine·Alvar G N AgustíXavier Busquets
Sep 3, 2002·American Journal of Respiratory and Critical Care Medicine·Nicholas R AnthonisenRobert P Murray
Jun 21, 2003·American Journal of Respiratory and Critical Care Medicine·Elizabeth GamblePeter K Jeffery
Mar 3, 2004·American Journal of Respiratory and Critical Care Medicine·Tom M A WilkinsonJadwiga A Wedzicha
Mar 5, 2004·The New England Journal of Medicine·Bartolome R CelliHoward J Cabral
Jun 25, 2004·The New England Journal of Medicine·James C HoggPeter D Paré
Jun 29, 2004·The European Respiratory Journal·W T McNicholasUNKNOWN Tiotropium Sleep Study in COPD Investigators
Aug 20, 2004·Nature Reviews. Drug Discovery·Cynthia Mundy, Peter Kirkpatrick
Oct 2, 2004·The European Respiratory Journal·O HolzR A Jörres
Feb 16, 2005·Annals of Internal Medicine·Nicholas R AnthonisenUNKNOWN Lung Health Study Research Group
Aug 23, 2005·Proceedings of the American Thoracic Society·Don D Sin, S F Paul Man
Sep 15, 2005·JAMA : the Journal of the American Medical Association·Ahmedin JemalMichael Thun
Feb 10, 2007·American Journal of Respiratory and Critical Care Medicine·Stephen I RennardUNKNOWN COPD Investigators
Feb 21, 2007·Annals of Internal Medicine·Shawn D AaronUNKNOWN Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium
Feb 23, 2007·The New England Journal of Medicine·Peter M A CalverleyUNKNOWN TORCH investigators
Apr 21, 2007·American Journal of Respiratory and Critical Care Medicine·Peter J Barnes
May 17, 2007·The European Respiratory Journal·E GambleN C Barnes
May 18, 2007·American Journal of Respiratory and Critical Care Medicine·Klaus F RabeUNKNOWN Global Initiative for Chronic Obstructive Lung Disease

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
pharmacotherapies

Software Mentioned

UPLIFT
TORCH

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.